Incannex CEO AGM address to shareholders

“Considering weakened market conditions on the Nasdaq and more specifically the Nasdaq Biotech Index, which has corrected circa 20% in recent months, we have decided to complete our Nasdaq listing without an associated capital raise so that all variables associated with listing are under the Company’s control.”

Mr Joel Latham, CEO and Managing Director.